Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate
• * High-risk, locally advanced disease (T2b-T4 disease), meeting 1 of the following criteria:
• * Gleason score 8-10
• * Prostate-specific antigen \> 20 ng/dL AND Gleason score 7
• * T2a disease allowed provided ≥ 5 biopsies contain Gleason score 4 +3 cancer (minimum of 10 biopsies total required)
• No evidence of metastatic disease within the past 60 days by physical examination, chest x-ray, bone scan, and CT scan of abdomen and pelvis
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Hemoglobin \> 8 g/dL
• Absolute granulocyte count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• Creatinine ≤ 1.5 times ULN
• Blood pressure ≤ 150/100 mm Hg
• No cardiovascular disease, including any of the following:
• * Unstable angina
• * New York Heart Association class II-IV congestive heart failure
• * History of myocardial infarction within the past 6 months
• * History of stroke within the past 6 months
• PRIOR CONCURRENT THERAPY:
• At least 4 weeks since prior major surgery
• No prior hormonal therapy (except finasteride for obstructive voiding symptoms) for prostate cancer
• No prior or concurrent chemotherapy, biologic therapy, or radiotherapy for prostate cancer